Kamau Therapeutics
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease (NCT04819841) | Kamau Therapeutics | 2021-11-15 |
Track Kamau Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.